Anal cancer occurs when malignant (cancer) cells form in the tissues of the anus. Anal cancer accounts for approximately 1 to 2 percent of all gastrointestinal cancers diagnosed.
At Penn Medicine, our Gastrointestinal Cancer Program is leading the way nationally in the diagnosis and treatment of gastrointestinal malignancies. Our multidisciplinary approach to care provides better outcomes and gives patients access to the most advanced treatment, surgical techniques and clinical trials. Support from a robust research program allows for immediate translation from bench to bedside. This approach has a dual goal of anal conservation and cure of disease.
Every step of anal cancer treatment, from a cancer diagnosis and treatment, to forming a survivorship plan, comes with different needs and issues that should be addressed.
Oncology navigators are committed to making sure every patient experience is as comfortable as possible. They are experts in navigating complex health care situations and serve as a consistent point of contact and a reliable source for advice, support and direction for patients and families.